or
Remember me
Back
3:45 pm: Voting begins on the final question: does the risk-benefit assessment support approval for tesamorelin?
The final vote is as follows:Yes: 16No: 0Abstain: 0
Receive investor kits and email updates from Stockhouse and directly from these companies.